Academic and Research Skills
Advocacy
Children with Chronic Conditions
Clinical Research
Community Pediatrics
COVID-19
Developmental and Behavioral Pediatrics
Diversity, Equity, and Inclusion
Environmental Health
General Pediatrics
Health Equity/Social Determinants of Health
Infectious Diseases
Public Health
Rachel Gross, MD, MS (she/her/hers)
Assistant Professor of Pediatrics and Population Health
New York University Grossman School of Medicine
New York, New York, United States
Session
Description: This session is a presentation by pediatric RECOVER (Researching COVID to Enhance Recovery) research investigators. RECOVER is an NIH-funded national multi-site observational study to learn about the long-term effects of COVID in children, with >100 sites across the US, actively recruiting ~20,000 caregiver-child dyads between birth and 25 years old, with ~6,000 being followed longitudinally for up to 4 years. RECOVER includes diverse recruitment efforts (e.g., community-based, health care-based, and pregnancy cohorts) and data collection methods (e.g., surveys, direct assessments including neurocognitive and anthropometric, and biospecimen collection), which will foster research in multiple scientific domains across the life course. RECOVER aims to understand recovery from a COVID infection and develop a pediatric definition of Long COVID or PASC (post-acute sequelae of SARS-CoV-2).
This session brings together national experts from RECOVER to describe what is known about Long COVID in children, why it is important, and how RECOVER is addressing the limitations of prior COVID-related studies. The session will describe the RECOVER initiative and will summarize the existing evidence related to: 1) What is the RECOVER initiative?; 2) What are the prevailing characteristics to date of Long COVID in children?; 3) What are the potential risk and resiliency factors associated with developing Long COVID?; 4) What is known about how long COVID affects child physical health, mental health and development and how will RECOVER data help to ultimately elucidate mechanisms of impact?; and 5) What is known about how prenatal exposure to SAR-CoV-2 during pregnancy affects infant health and development?
Speaker: Rachel S. Gross, MD, MS (she/her/hers) – New York University Grossman School of Medicine
Speaker: Sindhu Mohandas, MD, MRCPCH (she/her/hers) – Children's Hospital Los Angeles
Speaker: Kyung (Kay) E. Rhee, MD, MSc, MA (she/her/hers) – University of California, San Diego School of Medicine
Speaker: Melissa Stockwell, MD MPH (she/her/hers) – Columbia University Vagelos College of Physicians and Surgeons
Speaker: Valerie J. Flaherman, MD, MPH (she/her/hers) – University of California, San Francisco, School of Medicine